BioGaia AB (publ) (BIOG-B) - Total Assets
Based on the latest financial reports, BioGaia AB (publ) (BIOG-B) holds total assets worth Skr1.60 Billion SEK (≈ $171.95 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BioGaia AB (publ) shareholders equity for net asset value and shareholders' equity analysis.
BioGaia AB (publ) - Total Assets Trend (2002–2025)
This chart illustrates how BioGaia AB (publ)'s total assets have evolved over time, based on quarterly financial data.
BioGaia AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
BioGaia AB (publ)'s total assets of Skr1.60 Billion consist of 76.3% current assets and 23.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr801.31 Million | 50.2% |
| Accounts Receivable | Skr216.17 Million | 13.5% |
| Inventory | Skr166.70 Million | 10.4% |
| Property, Plant & Equipment | Skr181.15 Million | 11.3% |
| Intangible Assets | Skr702.00K | 0.0% |
| Goodwill | Skr146.50 Million | 9.2% |
Asset Composition Trend (2002–2025)
This chart illustrates how BioGaia AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BioGaia AB (publ) (BIOG-B) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioGaia AB (publ)'s current assets represent 76.3% of total assets in 2025, a decrease from 79.9% in 2002.
- Cash Position: Cash and equivalents constituted 50.2% of total assets in 2025, down from 74.6% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 15.0% in 2002.
- Asset Diversification: The largest asset category is cash and equivalents at 50.2% of total assets.
BioGaia AB (publ) Competitors by Total Assets
Key competitors of BioGaia AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
BioGaia AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.12 | 7.81 | 14.18 |
| Quick Ratio | 5.28 | 7.07 | 14.18 |
| Cash Ratio | 4.02 | 5.94 | 0.00 |
| Working Capital | Skr1.02 Billion | Skr1.40 Billion | Skr1.59 Billion |
BioGaia AB (publ) - Advanced Valuation Insights
This section examines the relationship between BioGaia AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.00 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | Skr1.60 Billion |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BioGaia AB (publ)'s assets below their book value (0.79x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioGaia AB (publ)'s assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioGaia AB (publ) (2002–2025)
The table below shows the annual total assets of BioGaia AB (publ) from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.60 Billion ≈ $171.95 Million |
-21.45% |
| 2024-12-31 | Skr2.03 Billion ≈ $218.89 Million |
-12.82% |
| 2023-12-31 | Skr2.33 Billion ≈ $251.09 Million |
+5.39% |
| 2022-12-31 | Skr2.21 Billion ≈ $238.26 Million |
+4.04% |
| 2021-12-31 | Skr2.13 Billion ≈ $229.01 Million |
+11.23% |
| 2020-12-31 | Skr1.91 Billion ≈ $205.90 Million |
+187.32% |
| 2019-12-31 | Skr665.90 Million ≈ $71.66 Million |
+0.90% |
| 2018-12-31 | Skr659.97 Million ≈ $71.02 Million |
+14.56% |
| 2017-12-31 | Skr576.11 Million ≈ $62.00 Million |
+17.82% |
| 2016-12-31 | Skr488.98 Million ≈ $52.62 Million |
+3.34% |
| 2015-12-31 | Skr473.18 Million ≈ $50.92 Million |
+13.85% |
| 2014-12-31 | Skr415.61 Million ≈ $44.73 Million |
+8.40% |
| 2013-12-31 | Skr383.42 Million ≈ $41.26 Million |
-25.84% |
| 2012-12-31 | Skr517.02 Million ≈ $55.64 Million |
+84.76% |
| 2011-12-31 | Skr279.83 Million ≈ $30.11 Million |
+22.83% |
| 2010-12-31 | Skr227.82 Million ≈ $24.52 Million |
+26.70% |
| 2009-12-31 | Skr179.81 Million ≈ $19.35 Million |
+16.53% |
| 2008-12-31 | Skr154.31 Million ≈ $16.61 Million |
+39.30% |
| 2007-12-31 | Skr110.77 Million ≈ $11.92 Million |
+22.05% |
| 2006-12-31 | Skr90.76 Million ≈ $9.77 Million |
+4.14% |
| 2005-12-31 | Skr87.15 Million ≈ $9.38 Million |
-19.68% |
| 2004-12-31 | Skr108.51 Million ≈ $11.68 Million |
-20.16% |
| 2003-12-31 | Skr135.90 Million ≈ $14.63 Million |
-15.92% |
| 2002-12-31 | Skr161.63 Million ≈ $17.39 Million |
-- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more